Le Lézard
Classified in: Health
Subjects: NPT, LAW, WOM, AVO

Family Research Council Celebrates Court Win for New Title X Rule, Calls it Important Step toward Ending Title X's Forced Partnership with the Abortion Industry


WASHINGTON, June 20, 2019 /PRNewswire/ -- The U.S. Court of Appeals for the Ninth Circuit just ruled that the Trump administration's regulations governing the Title X family planning program can go into effect while court proceedings play out. The Protect Life Rule at issue in this case ensures the integrity of the Title X program by preventing the "co-location" of federally funded family planning clinics with abortion clinics. The announcement comes a day after the Department of Health and Human Services strongly defended the new Title X regulations in front of a House Energy and Commerce Subcommittee. Family Research Council Vice President for Policy Travis Weber commented:

Family Research Council logo (PRNewsFoto/Family Research Council)

"With today's decision, President Trump's HHS is able to proceed with implementing the new Title X rule. The finalized 'protect life rule' will draw a bright line between abortion and family planning programs -- just as federal law requires and the Supreme Court has upheld.

"It's a shame that the federal Title X family planning program has been co-mingled with abortion ever since President Bill Clinton issued regulations not only removing the barrier of separation President Reagan put in place, but even illegally requiring groups to refer for abortion. The result is that Planned Parenthood ? an organization that's been under investigation for selling baby body parts ? gets roughly $60 million per year through what has become a slush fund for the abortion giant.

"To comply with this rule, Title X clinics must maintain both physical and financial separation from abortion services and will no longer be allowed to refer clients for abortions. While we await the final ruling on the merits of this case, today's ruling from the Ninth Circuit is a great first step in ending the forced partnership between the Title X program and the abortion industry," concluded Weber.

 

SOURCE Family Research Council


These press releases may also interest you

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

24 avr 2024
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

24 avr 2024
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

24 avr 2024
Valcare Medical, Inc., a leading innovator in transcatheter-based mitral...



News published on and distributed by: